As the United States flounders to meet its COVID-19 vaccine targets—only 49% of Americans are fully vaccinated to date.
The especially contagious Delta variant has the daily number of new cases back on the upswing, with a 171% increase in new cases compared to two weeks ago.
Around the world, the situation is even more dire.
Despite the fact that experts predict nearly 11 billion doses of vaccine will have been manufactured by the end of 2021, vaccines are not accessible by the vast majority of people who live outside the world’s highest-income countries.
“…it’s like watching a slow-moving train wreck, despite having developed the scientific tools to stop it.”
On Wednesday, Boston University’s Center for Emerging Infectious Diseases Policy & Research (CEID) convened a panel of experts to provide a briefing on the pitfalls that have so far prevented COVID-19 vaccines from reaching the world’s most vulnerable populations, and what challenges lie ahead in pursuit of the goal for 40% of the world population to receive a COVID-19 vaccine by the end of 2021.
That goal, and a longer-range one of having 60% of the world vaccinated by mid-2022, was proposed earlier this year at the G20 Global Health Summit by Kristalina Georgieva, managing director of the International Monetary Fund (IMF).
US Congresswoman Lois Frankel (D-Florida), kicked off the panel with opening remarks, saying, “the pandemic has taught us how truly connected we are on this planet.” Given that the coronavirus has shown no regard whatsoever for state or national borders, and due to the influence that globalization has had on spreading COVID-19 across all seven continents, Frankel says “we have a lot of work to do in preventing and responding to [future] pandemics” like this one.
In the briefing, global health experts Nahid Bhadelia, founding director of the CEID, Josh Michaud, associate director of global health policy at the Kaiser Family Foundation, and Mosoka Fallah, president and CEO of Refuge Place International, discussed ways that US policymakers can help ensure people around the world have equitable access to coronavirus vaccine—a strategy that will also protect the health of Americans.
With Delta driving coronavirus cases toward another US-wide spike, and many Americans still hesitating to get vaccinated, Maxmen says, “it’s like watching a slow-moving train wreck, despite having developed the scientific tools to stop it.”
Here are the top six takeaways from the panel discussion:
Delays in getting COVID-19 vaccines to middle- and low-income countries are causing devastation in multiple ways.
Bhadelia says that 115,000 health care workers have died from coronavirus globally, which is “a big deal in [areas of the world] where there are only one or two doctors” caring for people spread across large, rural geographic regions. She adds that the stressors of the pandemic have also pushed 95 million more people into extreme poverty, and brought 130 million people to the brink of starvation, due to economic and food scarcity.
What’s more, she says, research from the IMF reveals that the wealth gap between the world’s richest and poorest will become more extreme following a pandemic. The more time that lapses between when high-income countries become largely vaccinated and when vaccines reach the lowest-income countries, the greater income inequality will increase. In turn, this dynamic can breed political instability.
The arrival of vaccines in the US has lulled us into believing the pandemic is dwindling.
The US has been so focused on dealing with its own surges—which are now on the rise again—that Bhadelia says we haven’t properly turned our eyes to “how bad things are globally, and how bad they’re going to be for a while.”
The magnitude of the pandemic, she says, is becoming more and more exacerbated by many of the world’s most vulnerable populations slipping further and further into poverty. As if the current pandemic weren’t problematic enough, Bhadelia says extreme poverty further breaks down the boundaries between humans and animals, and provides even more opportunity for pathogens like SARS-CoV-2 to jump between species and develop as new emerging infectious diseases.
A big percentage of vaccines expected to be manufactured by the end of 2021 has already been spoken for.
Michaud says that even though 11 billion total doses will have been created by the end of 2021, 9.9 billion of those doses are already promised to higher-income countries and upper-middle-income countries. “Despite the fact that high-income countries make up 15% of the world population, [they’ve spoken for] 40% of the [expected] global vaccine supply,” he says.
That will further widen the spread of the percentage of people vaccinated per country, which already has a yawning gap between high-income countries (51% of people vaccinated) and low-income countries (1% of people vaccinated). Upper-middle-income countries and lower-middle-income countries are currently 31 and 14% vaccinated, respectively.
“At the current pace, disparities will grow… low-income countries will not reach the global vaccination target of being 40% vaccinated by the end of 2021,” Michaud says. To do that, “they would need to increase their daily vaccination rate by 19 times,” starting immediately.
G7 countries have committed to donating 1 billion doses of COVID vaccines to low-income areas by mid-2022. But as promising as that sounds, only 100 million such doses have been delivered globally to date.
Vaccines are the limiting factor in determining which countries will experience “mass fatality” situations due to COVID-19.
Fallah says that lack of access to vaccines has created mass fatality situations in many countries in Africa, saying, “83% of new deaths are from COVID-19 in Namibia, South Africa, Tunisia, Uganda, and Zambia.”
That’s largely due, in part, to the fact that, in addition to not having vaccines, these countries lack the infrastructure to manufacture enough supplemental oxygen for their COVID-19 patients. In Uganda, existing infrastructure can handle producing 3,000 cylinders of oxygen per day. Right now, the number of COVID-19 patients in Uganda requires 25,000 cylinders per day.
“Africa is running out of oxygen,” Fallah says.
Countries like Uganda that don’t have the capacity to manufacture oxygen, life-saving drugs, or other tools to improve survival from COVID-19 infection, are where surplus vaccines are most badly needed to be delivered. But that’s not what is happening.
“Political will”—or lack of it—is preventing surplus vaccines, like the many doses stockpiled here in the US, from being donated and delivered to low-income countries.
Why is that? Bhadelia says it has to do with the way the agreements were set up between the Trump administration’s Operation Warp Speed and vaccine manufacturers. “There’s a limit on exports,” she says. “It’s a ‘political will’ issue.”
“Where there’s a will, there’s a way,” Michaud agreed, although he says he does not know all the details of the legal agreements made by Operation Warp Speed. “AstraZeneca vaccines have been able to be donated…. If there was enough push on this, these doses of [Moderna, Pfizer, and Johnson & Johnson vaccines] that have been distributed around the country [could be delivered to other countries that need them desperately and want to use them now]. There could be logistical issues of getting them there, but these are solvable issues.”
It’s an extremely frustrating conundrum for Bhadelia to see. “This is not business as usual, [where we can afford to] wait until we figure out the legalities,” she says. During the recent coronavirus surge in India, she lost three members of her extended family. Meanwhile, despite how flush the US is with vaccine supplies, she has been navigating challenging conversations with some her patients at Boston Medical Center who are hesitant or opposed to getting the life-saving vaccine.
Donating surplus vaccines to countries that need them will not jeopardize Americans’ access to boosters.
Bhadelia says that if booster vaccines are needed in the near term, it will most likely only be recommended for a smaller portion of the US population—namely, people aged 65 or older, immunocompromised people, or those who didn’t receive a high level of protection from their initial vaccination.
“It makes sense to reserve boosters for a small portion of the population, but distributing [surplus] vaccines more widely—quickly—is how we will keep the US safe.”
That’s because with the Delta variant spreading as fast as it is throughout the world, the virus is getting countless more opportunities to mutate. Every time the virus transmits from one person to another, it changes slightly. With enough new changes and combinations, increasingly contagious and potentially deadly versions of coronavirus could emerge.
Source: Boston University